Note 6. Income Taxes
Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s deferred tax assets at August 31, 2017 and 2016 are as follows:
| Year Ended | ||||||||
| August 31, | ||||||||
| 2017 | 2016 | |||||||
| Deferred tax assets: | ||||||||
| Net operating loss carryforwards | $ | 174,156 | $ | 169,710 | ||||
| Capitalized research and development | 998 | 2,577 | ||||||
| Research and development credit carry forward | 1,963 | 1,963 | ||||||
| Total deferred tax assets | 177,117 | 174,250 | ||||||
| Less: valuation allowance | (177,117 | ) | (174,250 | )) | ||||
| Net deferred tax asset | $ | — | $ | — | ||||
The net increase in the valuation allowance for deferred tax assets was $2,867 and $2,660 for the years ended August 31, 2017 and 2016. The Company evaluates its valuation allowance on an annual basis based on projected future operations. When circumstances change and this causes a change in management’s judgment about the realizability of deferred tax assets, the impact of the change on the valuation allowance is reflected in current operations.
For federal income tax purposes, the Company has net U.S. operating loss carry forwards at August 31, 2017 available to offset future federal taxable income, if any, of $512,224, which will fully expire by the fiscal year ended August 31, 2035. Accordingly, there is no current tax expense for the years ended August 31, 2017 and 2016. In addition, the Company has research and development tax credit carry forwards of $1,963 at August 31, 2017, which are available to offset federal income taxes and fully expire by August 31, 2028.
The utilization of the tax net operating loss carry forwards may be limited due to ownership changes that have occurred as a result of sales of common stock.
The effects of state income taxes were insignificant for the years ended August 31, 2017 and 2016.
The following is a reconciliation between expected income tax benefit and actual, using the applicable statutory income tax rate of 34% for the years ended August 31, 2017 and 2016:
| Year Ended | ||||||||
| August 31, | ||||||||
| 2017 | 2016 | |||||||
| Income tax benefit at statutory rate | $ | 2,867 | $ | 2,660 | ||||
| Change in valuation allowance | (2,867 | ) | (2,660 | ) | ||||
| $ | — | $ | — | |||||
The fiscal years 2012 through 2017 remain open to examination by federal authorities and other jurisdictions in which the Company operates.
On December 22, 2017, the Tax Cuts and Jobs Act was enacted. This law substantially amended the Internal Revenue Code, including reducing the U.S. corporate tax rates. Upon enactment, the Company’s deferred tax asset and related valuation allowance decreased by $66,970 to $110,147. As the deferred tax asset is fully allowed for, this change in rates had no impact on the Company’s financial position or results of operations.